110 related articles for article (PubMed ID: 16310074)
1. Adverse event reporting for botulinum toxin type A.
Batra RS; Dover JS; Arndt KA
J Am Acad Dermatol; 2005 Dec; 53(6):1080-2. PubMed ID: 16310074
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
[TBL] [Abstract][Full Text] [Related]
3. Complications of botulinum toxin type A.
Carruthers J; Carruthers A
Facial Plast Surg Clin North Am; 2007 Feb; 15(1):51-4, vi. PubMed ID: 17317555
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.
Hamdy RC; Montpetit K; Raney EM; Aiona MD; Fillman RR; MacKenzie W; McCarthy J; Chafetz RS; Thomas SS; Tamayo CM; Littleton AG; Ruck-Gibis J; Takahashi SN; Rinaldi M; Finley GA; Platt RW; Dahan-Oliel N
J Pediatr Orthop; 2009; 29(5):427-34. PubMed ID: 19568011
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity.
Turkel CC; Bowen B; Liu J; Brin MF
Arch Phys Med Rehabil; 2006 Jun; 87(6):786-92. PubMed ID: 16731213
[TBL] [Abstract][Full Text] [Related]
6. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
[TBL] [Abstract][Full Text] [Related]
7. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
[TBL] [Abstract][Full Text] [Related]
8. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis.
Pena MA; Alam M; Yoo SS
Semin Cutan Med Surg; 2007 Mar; 26(1):29-33. PubMed ID: 17349560
[TBL] [Abstract][Full Text] [Related]
9. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
Moore TJ; Cohen MR; Furberg CD
Arch Intern Med; 2007 Sep; 167(16):1752-9. PubMed ID: 17846394
[TBL] [Abstract][Full Text] [Related]
10. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
Kuo HC
Urology; 2006 Nov; 68(5):993-7; discussion 997-8. PubMed ID: 17113890
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
14. Malfunctions and adverse events associated with off-label use of biliary stents in the peripheral vasculature.
Bridges J; Maisel WH
Am J Ther; 2008; 15(1):12-8. PubMed ID: 18223348
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A in prophylactic treatment of migraine.
Anand KS; Prasad A; Singh MM; Sharma S; Bala K
Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A in the treatment of sialorrhea.
Benson J; Daugherty KK
Ann Pharmacother; 2007 Jan; 41(1):79-85. PubMed ID: 17190848
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea.
Su CS; Lan MY; Liu JS; Chang CC; Lai SL; Wu HS; Chen SS; Chang YY
Acta Neurol Taiwan; 2006 Sep; 15(3):170-6. PubMed ID: 16995596
[TBL] [Abstract][Full Text] [Related]
18. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
20. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
